Lianhuan Pharmaceutical plans to collaborate with Nanjing University to jointly conduct research and development of anti-thrombotic small nucleic acid drugs
November 19, 2025
Source: drugdu
77
Shanghai Securities News (Reporter He Xinyi) - On November 19th, Lianhuan Pharmaceutical announced that the company intends to collaborate with Nanjing University to jointly develop "anti-thrombotic small nucleic acid drugs", with an investment amount of 15 million yuan. It is known that this cooperation aims to leverage Nanjing University's strong research capabilities and preliminary research foundation in nucleic acid drugs, combined with the company's industrialization and clinical development capabilities, to jointly promote the research and commercialization of innovative drugs.
https://finance.eastmoney.com/a/202511193568677315.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- U.S. ERs Are Failing Sickle Cell Patients In Pain, Study Says December 11, 2025
- GLP-1 Medications Show Little Effect on Cancer, Study Shows December 11, 2025
- Qilu Pharmaceutical wins blockbuster new drug December 11, 2025
- Originating from traditional Chinese medicine, it defeated dapagliflozin head-to-head December 11, 2025
- Tencent invests in RNA innovative drug R&D company Hongxin Bio December 11, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
